← Back to Search

MRI Evaluation for Spinal Cord Injury (CHASM Trial)

N/A
Recruiting
Led By Brian Kwon, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Acute tSCI injury involving bony spinal levels between C0 and T1
Be older than 18 years old
Must not have
Spinal cord injury due to infection
Pathological fracture due to metabolic condition or neoplasia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up injury to 6 months post injury
Awards & highlights

Summary

This trial tests if raising blood pressure and preventing blood clots can help with bleeding in the spinal cord after an injury. It focuses on patients with a specific type of spinal injury and aims to manage blood flow and prevent clots to improve recovery. A medication is used to maintain higher blood pressure in patients with recent spinal cord injuries to support better outcomes.

Who is the study for?
This trial is for adults aged 19 or older who have suffered a traumatic spinal cord injury between the base of the skull and top of the chest (C0-T1) and are admitted to the study site within a day. They must be able to consent and have certain levels of impairment. Those with MRI-incompatible devices, very high BMI, incomplete assessments, injuries from infection or cancer, or multiple severe injuries can't join.
What is being tested?
The study uses MRI scans to see if treatments right after a spinal cord injury affect bleeding in the spine. It looks at two things: whether raising blood pressure with drugs (vasopressors) and preventing blood clots with anticoagulants influence hemorrhage during the first two weeks post-injury.
What are the potential side effects?
MRI itself doesn't usually cause side effects but lying still in a scanner might be uncomfortable for some people. The focus here is on observing changes rather than direct side effects from interventions like vasopressors or anticoagulants.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My spinal injury is between the base of my skull and the top of my mid-back.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My spinal cord injury was caused by an infection.
Select...
I have a broken bone caused by a disease or cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~injury to 6 months post injury
This trial's timeline: 3 weeks for screening, Varies for treatment, and injury to 6 months post injury for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Hemorrhage Quantification 1
Hemorrhage Quantification 2
Hemorrhage Quantification 3
+1 more
Secondary study objectives
Hemodynamic Management Assessment 1
Hemodynamic Management Assessment 2
Other study objectives
Neurologic Assessments

Trial Design

1Treatment groups
Experimental Treatment
Group I: Arm 1Experimental Treatment1 Intervention
Serial MRI scans of patients with acute cervical SCI to quantify hemorrhage.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic resonance imaging (MRI)
2019
Completed Phase 4
~1080

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for spinal cord hemorrhage include MAP augmentation with vasopressors and VTE prophylaxis with anticoagulants. MAP augmentation with vasopressors works by increasing blood pressure, which improves spinal cord perfusion and helps to ensure that the injured spinal cord receives adequate oxygen and nutrients, potentially limiting further damage. VTE prophylaxis with anticoagulants prevents the formation of blood clots, which is crucial because patients with spinal cord injuries are at a higher risk for venous thromboembolism due to immobility. Preventing blood clots reduces the risk of additional complications, such as pulmonary embolism, which can be life-threatening. Together, these treatments aim to stabilize the patient's condition and prevent secondary injuries, improving overall outcomes.
Cerebral Hemorrhage Following Chiropractic Activator Treatment - Case Report and Review of Literature.The role of hemorrhage following spinal-cord injury.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,451 Previous Clinical Trials
2,483,166 Total Patients Enrolled
United States Department of DefenseFED
891 Previous Clinical Trials
332,454 Total Patients Enrolled
Brian Kwon, MDPrincipal InvestigatorUniversity of British Columbia
3 Previous Clinical Trials
130 Total Patients Enrolled

Media Library

Magnetic resonance imaging (MRI) Clinical Trial Eligibility Overview. Trial Name: NCT04758377 — N/A
Spinal Cord Hemorrhage Research Study Groups: Arm 1
Spinal Cord Hemorrhage Clinical Trial 2023: Magnetic resonance imaging (MRI) Highlights & Side Effects. Trial Name: NCT04758377 — N/A
Magnetic resonance imaging (MRI) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04758377 — N/A
~5 spots leftby Sep 2025